抄録_46回中国地方会37-6_責.indd



Similar documents
抄録36-6偶_中国_責.indd

41-6_50回中国地方会Pr6N__HP掲載用.indd

084_41-1_23四国CS6_念*.indd

42-2_26回関東甲信越地方会Pr6N_念*.indd

04_学術.indd

41-6_35回中部地方会Pr6N_HP掲載用.indd

092_41-1_23九州CS6_責.indd

₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3

評価結果報告書の概要版(平成20年度)

03-07プ_一般口演_責*.indd

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx

169_39-2_23関東甲信越_念*.indd

抄録37-2関西36_責.indd

02-56fl]’_„o68fl]”îá⁄-…v…“…O…›…•

IVR232.indb

S22 vol. 38 Suppl JA :35 15: JA :20 16:

ÿþ


untitled

049_41-1_43北海道CS6_念*.indd

11 第25回がん学会一般演題一覧(第3会場)

,

04_ポスター.indb

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

JSACHD_Vol5_No3_Dec2016.book

‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01

パネルディスカッション 2 Q 専門領域について選択してください 1. 消化器内科 2. 消化器外科 3. 放射線科 1% 4% 3% 21% 4. その他の医師 5. その他 ( 医師以外 ) 71%

/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg

デスフルラン

59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

がん診療におけるFDG FDG-PET/CTの役割

天草郡市医師会第139回(臨時)代議員会

1 Q A 82% 89% 88% 82% 88% 82%

01-表紙から目次.PDF

- 9 91, (2006)


0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2


1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC ml Syphilis TPAb Alb 2.7 g dl RBC ml HBsAg T. bil 2.3 mg dl Hb 11 g dl

(1) (2) (3) (4) (5) 2.1 ( ) 2

22肝胆膵_抄録_1_ indd

スライド 1

福岡大学人文論叢47-3

untitled

PowerPoint Presentation

GL_尾崎班_D.indd

indd

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

日本呼吸器学会雑誌第44巻第7号

_06.indd

慈大呼吸器_25-1_02T_CS5.indd

pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons

被曝二世健康影響調査

高脂血症の検査

PR E/A, PVR 1, 2, 2, 3, 3, 3, 3, 4, 5, 2 1, 2, 3, 4, 5,ASE, ,21 54, sniff 5 5,2 ASE,, 21 mm 20 sniff 50 3 mmhg, 21 mm 20 sniff mmhg, 8 m

次世代育成支援行動計画

PET-CT

: 1 : 50 mm : RCC 4 FFP ml 2. 1 : MRI : T2 6 cm flow void : Gd T1 UAE UAE 4 57

会場へのご案 内 駐車場のご用意がございませんので ご来場の際は 公共の交通機関等をご利用くださるよう お願い申しあげます 電車をご利用の場合 JR 横浜市営地下鉄線 桜木町駅下車 動く歩道利用 5 分 みなとみらい線 みなとみらい駅下車 クイーンズスクエア連絡口 けやき通り口 より徒歩 7 分 新

THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr B 2 NTT

2

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10

07.報文_及川ら-二校目.indd

マニュアル第4版表紙PDF

成人病(1).PDF

「東日本大震災に係る対応―保険診療・地域医療再生基金・災害復旧費補助金・医療法等について(第1報)」について

untitled

急性型から慢性肺血栓塞栓症性肺高血圧症に移行した1例


BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI

30 Fisher 2 t 結果 FIM 3 FIM ADL 考察 FIM ADL ADL ADL 結論 ADL 50 FIM ADL FIM 今後の展望 ADL 30 ADL ADL 1 FIM

03_学術.indd

02-06プ_一般ポスター_0407.indd

8 8 0

SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P

WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH

S S S S S

02_特別_共同_奨励.indb

General Instructional ObjectiveGIO Specific Behavioral ObjectivesSBOs (1) (2)

日本呼吸器学会雑誌第44巻第1号

2

ESD

- 1 -

Folie 1

051

全国循環器撮影研究会 HP講座No

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

051

Contents 4 06 IP2 41 Thermo Scientific Nalgene Nalgene

32, 15, 3 EUS TIC 1 db,eus EG SR EUS 60, 27, 24 EUS EG SR 0. 11, , EUS EUS EG ₂₆ ₆ 1, 2, 1, 1, 3, 2, 4, 1 1, 2, 3, 4 FibroScan,


無印良品 2012 自転車 カタログ

Th1 four lines C1-dens 3mm C1-C4 C4 7mm C5-C7 C7 22mm

HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly


untitled

(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..

日本呼吸器学会雑誌第47巻第6号

2015電磁波_歯科医.rtfd

Transcription:

46 22 9 11 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN 146 62 146 123 HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density 122 B A/B hypoechoic 75%/40%, hyperechoic 25%/60% P=0.001 MRI T1 A 6 25% B 69 57% P=0.004 EOB-MRI B 46-2 CTHA/CTAP 79 C CT MRI S4 4cm CTHA CTAP EOB-MRI TIWI T2WI Sonazoid US hypo echoic 30 2 iso echoic post vascular phase defect S4 US 46-3 planning sonography RVSCEUS 43 52 1. 2. RVS CEUS 3. 1. 1 23 4 2. good 9 fair 28 poor 12 invisible 3 good RVS fair poor invisible RVS CEUS 3. 96.2% 7.7% RVS CEUS 46-4 Sonazoid Sonazoid Sonazoid 15 Mechanical Index:0.2 focus TIC Sonazoid 0.010ml/kg TIC 25 39.5, 2.5-81.5 PT BMI Spleen Index Sonazoid 46-5 Sonazoid 70 2004 2009 8 10 CT 80mm

CT MRI Sonazoid 46-6 Sonazoid 70 B CT EOB-MRI Sonazoid Vascular phase Post-vascular phase Re-injection 6 5HIAA 46-7 Sonazoid DIC B Sonazoid CEUS 4 4 3 defect 1 defect B Sonazoid CEUS 46-8 10mm FNH 3 10mm FNH 40 51 73 3 CT S4 S5 S4 8-10mm B 3 central satellite scar spoke wheel appearance Sonazoid early arterial phase spoke wheel appearance late vascular phase Kupffer phase FNH HCC size FNH 46-9 1 70 H21 5 H22 6 CT Sonazoid 4 3500 ml 5%EOI Hct 5.9% 46-10 70 C 2009 4 AFP PIVKA 4 SOL 3 HCC S2 S2 10 US 12 CT 2010 4 US S2 S2 halo Sonazoid S2 S2 S2 HCC 46-11 1 85 spleen index 9.5 4.0 5cm CT

2cm 21G 46-12 73 PBC 22 2 S8 16mm Sonazoid early vascular phase late vascular phase Kupffer phase color doppler vascular phase penetrating vessel non-hodgkin lymphoma low grade B-cell lymphomapbc color doppler 46-13 1 70 17 CT MRI hypovascular metastasis color Doppler 15 metastasis retrospective review B-mode color Doppler hypervascular CT MRI 46-14 81 CT MRCP T-Bil3.7mg/dl ERCP EUS US hypovascular tumor EUSFNA 46-15 1 60 US US US CT MRI ERCP 50% IgG4 IgG4 / 46-16 EUS-FNA 1 46 LDH IgG US CT MRI DWI EUS capsule like rim ERCP EUS-FNA PET-CT FDG Burkitt lymphoma 46-17 80

DIC-CT 15mm EUS 2cm. 2cm 1 46-18 ss 76 US 8mm 14mm EUS 46-19 22 C 132 FibroScan Child Pugh Child Pugh P3P4 7s 46-20 C C C 3 C 55 0 1 23 4 FibroScan KPa HCV 5 46-21 AdaBoost 12 8 Cross-Validation 56% 85% 46-22 Virtual touch tissue quantification Virtual touch tissue quantification VTTQ (FIB4-index APRI 2009 1 2010 5 VTTQ 105 59 25-89 / 57/48 HBV/HCV 26/79 F cut off AUROC VTTQ; F1/2:1.195 0.875 0.8360.871 F2/3;1.565 0.938 0.9170.938 F3/4; 1.775 0.898 0.8570.961 FIB4;F1/2:17.13(0.750 0.7810.689 F2/3:28.16 0.716 0.542 0.689 F3/4:46.7(0.691 0.5710.651 APRI;F1/2:5.635 0.719 0.749 0.718 F2/3:9.93(0.691 0.6250.718 F3/4:11.17 0.728 0.542

0.552 VTTQ VTTQ 46-23 C C C 66 TOSHIBA APLIO XG F -3, A1-3 HARI, HAPI, SARI, SAPI, PVVmean Alb AST ALT -GTP, PLT SAPI SARI SAPI AST ALT AST ALT Update 46-24 EUS ESD EMR, ESD EUS 16 4 21 3 EMR,ESD387 202 52 51 98.1% 105 101 96.2% 13 3 23.1% 9 69.2% EMR, ESD 46-25 1 m sm1 4 13 17 3 75% 4 31% 3 75% 3 23% 46-26 EUS EUS 366 3 m 1mm sm 1mm m/sm EUS-m m/sm sm AD EUS-m 80.8% 194/240 EUS-sm 57.1% 28/49 8 EUS-m/sm 80.0% m 20.0% sm EUS 46-27 2009.4 2010.6 mp se n=33 mp 4 5 ss 5 ss 5 se ss 5

46-28 48 CT free air 5 US 30mm 46-29 52 SMA cm SMA SMA sandwich sign Castleman CT PET/CT 200cm 50cm myofibroblast 46-30 1 80 CT MRI CT 46-31 3 3 7 3 3 8 S 2cm 1 2cm 46-32 35 2009 12 X 8 8 40 US S US 20 / 3 US US S - US S 4 8 46-33

46-34 US EUS Sonazoid US EUS US 2007 6-2010 4 EUS 2009 10-2010 4 FNA 6 38 18 17 IPMN 14 mucus debris 1 NET 2 SPN 1 2 Sonazoid IPMN 46-35 58 19 15mm CT,MRI EUS-FNA 9 3 4cm CT Sonazoid EUS-FNA 46-36 IPMN 70 45mm 8.5mm 3 9 MRI Sonazoid 15mm ERCP ENPD IPMC 46-37 3D paillary fibroelastoma 72 Debakey 7 2002 21 9,,aVF ST 2D flap CT STEMI 100% flow flow 3D 10mm 3D paillary fibroelastoma 46-38 50 2004 12 4mm 2009 8 P2 13 10mm 46-39 61 21 6

3D 46-40 45 adenocarcinoma PET-CT FDG isoechoic 16 10mm 4 12 PET-CT 30 46-41 34 RT area trace 70 80% PSV peak systolic velocity 2.5m/s 1.7m/s 80% PSV 4.6m/s 3.6m/s 46-42 60 16 2009 3 6 Cr Cr 6.3mg/dl PSV 90% PTA PSV Cr 8 1.3mg/dl PTA 12 Cr 1.3mg/dl 46-43 MRA 3DCT 46-44 2D 45 22 5 1 2D dyssynchrony post systolic shortning 90% 2D 46-45 14 2

2 2 14 1 8,650/mm3 65%CRP 1.83mg/dl ESR 43/71 2 1 CRP 3 7mg/dl CT 46-46 28 H22 4 X effusion Myeloid/NK-cell acute leukemia effusion 46-47 18 67 21 8 X CT A-aDO2 46-48 spontaneous echo contrast spontaneous echo contrast 1 9 spontaneous echo contrast spontaneous echo contrast spontaneous echo contrast spontaneous echo contrast 46-49 15 1 55 15 CPA XP shuffle motion 46-50 Tei index Tei index 95%ile 12 2 4 3 1 3 1 1 Tei index 2 46-51 congenital absence of the portal vein: CAPV

26 16 CAPV 25 27 4 CAPV 1031g AS5/7 CAPV 46-52 3 three vessel view 3 38 11 2 39 PGE1 17 BT 22q11.2 3 trisomy21 37 NICU trisomy21 20 46-53 90% NICU 9 46-54 3 3 1 37 1 1 33 0 33 2 1704 g Apgar79 2 37 1 0 33 3 36 6 2332 g Apgar8/9 3 32 1 0 27 33 1 37 1 2618 g Apgar Score8/9 46-55 congenital pouch colon congenital pouch colon pouch colon 31 30 0 20 34 4 2321 g 1 1 5 5 ph 7.417 40 20 46-56 38 3 2 19 24 AFI 35cm 29 20ml/h 4 6500ml 33 1 3400g AS 1/5 Zimmerman-Laband 46-57 1 1

18 25 29 30 32 3 32 4 NST 3 46-58 34 21 5cm Tei index 28 35 4242g As 1/3 Hb3.5mg/dl 4 18 16 15cm 46-59 31 27 2 31 4 34 2 2,500ml 46-60 34 39 MTX 20 1 46-61 HCCRFA B-mode RFA CT margin B-mode Sonazoid RFA B-mode HCC TOSHIBA medical Aplio mode Sonazoid RFA CT CT RFA 1 RFA 46-62 1 60 2009 10 S8 15mm 1 RFA Sonazoid RFA 10ml 2 4 RFA 46-63 1 74 CT S4 35 US 21G Majima needle Debris CT CT

4 US CT 5 US 0.0059% US US 46-64 2008 12 6 VAS CT 15-20ml 2 46-65 2002 25 27 1 1 79mm 38-120mm GF-UCT240-AL5 Echotip Wilson Cook 19G EUS 14 96% 26/27 15% 4/27 4% 1/27 2 46-66 Carotidynia Carotidynia Carotidynia 1927 Fay 1967 Roseman 1988 the International Headache Society IHS classification committee 2004 Giant cell arteritis Carotidynia Carotidynia 46-67 1 50 30 46-68 RVS US 3D CT-lymphography SLN Real-time virtual sonography RVS US CT SLN US SLN US SLN ICG SLN SLN 137 136 99% ICG SLN 9 ICG SLN US SLN SLN SLN SLN 46-69 2 2 1 83 2 20mm 2 47 1

20mm 2 46-70 1 5 4 2.0cm 2.0cm CT MRI T1WI T2WI 46-71 1 20 3 16 IU/m FNAC classiv 46-72 1 30 CT 15 CT MRI 46-73 AVM AVM CT MRI AVM CT MRI AVM